Modeling based on IL-2 IC50 predicts up to 94% average daily inhibition at clinical dosage (28), which would suggest severe lymphopenia to be more prevalent with JAK1,2,3 inhibitor use. The gene discussed is IL2; the disease is lymphopenia.